Carnevale, Julia http://orcid.org/0000-0001-9410-7148
Shifrut, Eric http://orcid.org/0000-0001-6827-0128
Kale, Nupura http://orcid.org/0000-0002-3185-8646
Nyberg, William A.
Blaeschke, Franziska http://orcid.org/0000-0001-5770-4744
Chen, Yan Yi http://orcid.org/0000-0003-3611-2621
Li, Zhongmei
Bapat, Sagar P. http://orcid.org/0000-0002-4402-1511
Diolaiti, Morgan E. http://orcid.org/0000-0001-5900-3060
O’Leary, Patrick http://orcid.org/0000-0002-2919-5943
Vedova, Shane
Belk, Julia http://orcid.org/0000-0003-4724-6158
Daniel, Bence http://orcid.org/0000-0002-2410-8767
Roth, Theodore L.
Bachl, Stefanie
Anido, Alejandro Allo
Prinzing, Brooke
Ibañez-Vega, Jorge
Lange, Shannon
Haydar, Dalia
Luetke-Eversloh, Marie
Born-Bony, Maelys
Hegde, Bindu
Kogan, Scott http://orcid.org/0000-0002-2395-8479
Feuchtinger, Tobias http://orcid.org/0000-0002-8517-9681
Okada, Hideho http://orcid.org/0000-0003-0076-9920
Satpathy, Ansuman T. http://orcid.org/0000-0002-5167-537X
Shannon, Kevin http://orcid.org/0000-0003-4299-1773
Gottschalk, Stephen http://orcid.org/0000-0003-3991-7468
Eyquem, Justin http://orcid.org/0000-0001-8262-1190
Krenciute, Giedre http://orcid.org/0000-0003-4335-0644
Ashworth, Alan http://orcid.org/0000-0003-1446-7878
Marson, Alexander http://orcid.org/0000-0002-2734-5776
Article History
Received: 31 July 2021
Accepted: 20 July 2022
First Online: 24 August 2022
Competing interests
: J.E. is a compensated co-founder at Mnemo Therapeutics, a compensated scientific advisor to Cytovia Therapeutics, owns stocks in Mnemo Therapeutica and Cytovia Therapeutics and has received a consulting fee from Casdin Capital. The Eyquem laboratory has received research support from Cytovia Therapeutic and Takeda. J.E. is a holder of patents pertaining to but not resulting from this work. A.A. is a co-founder of Tango Therapeutics, Azkarra Therapeutics, Ovibio Corporation and Kytarro, a member of the boards of Cytomx and Cambridge Science Corporation, a member of the scientific advisory boards of Genentech, GLAdiator, Circle, Bluestar, Earli, Ambagon, Phoenix Molecular Designs and Trial Library, a consultant for SPARC, ProLynx and GSK, and a recipient of grant or research support from SPARC and AstraZeneca, and holds patents on the use of PARP inhibitors held jointly with AstraZeneca from which he has benefited financially (and may do so in the future). A.M. is a cofounder of Arsenal Biosciences, Spotlight Therapeutics and Survey Genomics, serves on the boards of directors at Spotlight Therapeutics and Survey Genomics, is board observer (and former member of the board of directors) at Arsenal Biosciences, is a member of the scientific advisory boards of Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics and NewLimit, owns stock in Arsenal Biosciences, Spotlight Therapeutics, NewLimit, Survey Genomics, PACT Pharma, and Merck, and has received fees from Arsenal Biosciences, Spotlight Therapeutics, NewLimit, 23andMe, PACT Pharma, Juno Therapeutics, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The Marson laboratory has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem. S.G. has a consulting agreement with Tessa Therapeutics, and is a compensated DSMB member of Immatics, and has received honoraria from Tidal, Catamaran Bio and Novartis within the last 2 years. The Gottschalk laboratory has received research support from Tessa Therapeutics. A.T.S. is a scientific founder of Immunai and founder of Cartography Biosciences and receives research funding from Arsenal Biosciences, Allogene Therapeutics and Merck Research Laboratories. H.O. has been a compensated consultant within the last 2 years for Bristol-Myers Squibb, Alexion Pharmaceuticals, Amal Therapeutics, Servier Pharmaceuticals, Neuvogen and Eureka Therapeutics. J.C., E.S., A.A. and A.M. are listed as inventors on a world patent application (WO2020014235A1) related to this work, <i>Gene Targets for T-cell-Based Immunotherapy</i>, which has been licensed.